514 related articles for article (PubMed ID: 31511439)
1. JCS 2017/JHFS 2017 Guideline on Diagnosis and Treatment of Acute and Chronic Heart Failure - Digest Version.
Tsutsui H; Isobe M; Ito H; Ito H; Okumura K; Ono M; Kitakaze M; Kinugawa K; Kihara Y; Goto Y; Komuro I; Saiki Y; Saito Y; Sakata Y; Sato N; Sawa Y; Shiose A; Shimizu W; Shimokawa H; Seino Y; Node K; Higo T; Hirayama A; Makaya M; Masuyama T; Murohara T; Momomura SI; Yano M; Yamazaki K; Yamamoto K; Yoshikawa T; Yoshimura M; Akiyama M; Anzai T; Ishihara S; Inomata T; Imamura T; Iwasaki YK; Ohtani T; Onishi K; Kasai T; Kato M; Kawai M; Kinugasa Y; Kinugawa S; Kuratani T; Kobayashi S; Sakata Y; Tanaka A; Toda K; Noda T; Nochioka K; Hatano M; Hidaka T; Fujino T; Makita S; Yamaguchi O; Ikeda U; Kimura T; Kohsaka S; Kosuge M; Yamagishi M; Yamashina A;
Circ J; 2019 Sep; 83(10):2084-2184. PubMed ID: 31511439
[No Abstract] [Full Text] [Related]
2. Almanac 2013: heart failure.
Clark AL
Heart; 2013 Nov; 99(21):1562-6. PubMed ID: 23996602
[No Abstract] [Full Text] [Related]
3. New guidelines, new recommendations! But what is really new? A pragmatic interpretation of the 2016 European guidelines for the management of chronic heart failure.
de Groote P; Cohen A; Juillière Y; Damy T
Arch Cardiovasc Dis; 2017 Jan; 110(1):1-6. PubMed ID: 28082242
[No Abstract] [Full Text] [Related]
4. Heart failure in search of a cure.
Torre-Amione G
Methodist Debakey Cardiovasc J; 2009; 5(3):1. PubMed ID: 20308956
[No Abstract] [Full Text] [Related]
5. Compelling First-Line Drug and Device Therapies for the Prevention of Sudden Death in Patients With Chronic Heart Failure and a Reduced Ejection Fraction Who Are Candidates for an Implantable Cardioverter-Defibrillator.
Packer M
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e007430. PubMed ID: 31159583
[No Abstract] [Full Text] [Related]
6. Reappraisal on pharmacological and mechanical treatments of heart failure.
Liang B; Zhao YX; Zhang XX; Liao HL; Gu N
Cardiovasc Diabetol; 2020 May; 19(1):55. PubMed ID: 32375806
[TBL] [Abstract][Full Text] [Related]
7. Reporting of Lost to Follow-Up and Treatment Discontinuation in Pharmacotherapy and Device Trials in Chronic Heart Failure: A Systematic Review.
Campbell RT; Willox GP; Jhund PS; Hawkins NM; Huang F; Petrie MC; McMurray JJ
Circ Heart Fail; 2016 May; 9(5):. PubMed ID: 27162229
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
9. [How to treat heart failure successfully].
Zobel C
MMW Fortschr Med; 2013 Mar; 155(4):41-6. PubMed ID: 23614195
[No Abstract] [Full Text] [Related]
10. Expert consensus guidelines: Anomalous aortic origin of a coronary artery.
Brothers JA; Frommelt MA; Jaquiss RDB; Myerburg RJ; Fraser CD; Tweddell JS
J Thorac Cardiovasc Surg; 2017 Jun; 153(6):1440-1457. PubMed ID: 28274557
[No Abstract] [Full Text] [Related]
11. Ventricular Electrical Delay Measured From Body Surface ECGs Is Associated With Cardiac Resynchronization Therapy Response in Left Bundle Branch Block Patients From the MADIT-CRT Trial (Multicenter Automatic Defibrillator Implantation-Cardiac Resynchronization Therapy).
Plesinger F; Jurak P; Halamek J; Nejedly P; Leinveber P; Viscor I; Vondra V; McNitt S; Polonsky B; Moss AJ; Zareba W; Couderc JP
Circ Arrhythm Electrophysiol; 2018 May; 11(5):e005719. PubMed ID: 29700054
[TBL] [Abstract][Full Text] [Related]
12. Cardiac Implantable Electronic Device Therapy in Heart Failure.
Hussein AA; Wilkoff BL
Circ Res; 2019 May; 124(11):1584-1597. PubMed ID: 31120815
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular implanted electronic devices in people towards the end of life, during cardiopulmonary resuscitation and after death: guidance from the Resuscitation Council (UK), British Cardiovascular Society and National Council for Palliative Care.
Pitcher D; Soar J; Hogg K; Linker N; Chapman S; Beattie JM; Jones S; George R; McComb J; Glancy J; Patterson G; Turner S; Hampshire S; Lockey A; Baker T; Mitchell S;
Heart; 2016 Jun; 102 Suppl 7():A1-A17. PubMed ID: 27277710
[TBL] [Abstract][Full Text] [Related]
14. Reduction of inappropriate anti-tachycardia pacing therapies and shocks by a novel suite of detection algorithms in heart failure patients with cardiac resynchronization therapy defibrillators: a historical comparison of a prospective database.
Lunati M; Proclemer A; Boriani G; Landolina M; Locati E; Rordorf R; Daleffe E; Ricci RP; Catanzariti D; Tomasi L; Gulizia M; Baccillieri MS; Molon G; Gasparini M;
Europace; 2016 Sep; 18(9):1391-8. PubMed ID: 26826135
[TBL] [Abstract][Full Text] [Related]
15. An individualized left ventricular lead-targeting strategy improves long-term survival of cardiac resynchronization therapy patients and influences the benefit of the implantable cardioverter-defibrillator: a long-term follow-up of the TARGET study.
Barra S; Yu E; Khan F; Dutka D; Virdee M
J Cardiovasc Med (Hagerstown); 2017 Jul; 18(7):553-555. PubMed ID: 27136703
[No Abstract] [Full Text] [Related]
16. Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT.
Skali H; Gerwien R; Meyer TE; Snider JV; Solomon SD; Stolen CM
J Cardiovasc Transl Res; 2016 Dec; 9(5-6):421-428. PubMed ID: 27798759
[TBL] [Abstract][Full Text] [Related]
17. Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy.
Gronda E; Genovese S; Padeletti L; Cacciatore F; Vitale DF; Bragato R; Innocenti L; Schiano C; Sommese L; De Pascale MR; Genovese L; Abete P; Donatelli F; Napoli C
Cardiol J; 2015; 22(4):459-66. PubMed ID: 26325259
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry.
Khazanie P; Greiner MA; Al-Khatib SM; Piccini JP; Turakhia MP; Varosy PD; Masoudi FA; Curtis LH; Hernandez AF;
Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27296396
[TBL] [Abstract][Full Text] [Related]
19. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%).
Lam CS; Solomon SD
Eur J Heart Fail; 2014 Oct; 16(10):1049-55. PubMed ID: 25210008
[No Abstract] [Full Text] [Related]
20. Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate.
Sardu C; Paolisso P; Sacra C; Santamaria M; de Lucia C; Ruocco A; Mauro C; Paolisso G; Rizzo MR; Barbieri M; Marfella R
Cardiovasc Diabetol; 2018 Oct; 17(1):137. PubMed ID: 30348145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
